The abstract is read at the publisher; the summary is JClub's.
Over the past 25 years, drug discovery has expanded its target landscape to 686 biomolecules modulated by 1,702 drugs, reflecting major shifts in target types.
- Why it matters: The field needed a mapped, quantified view of how genetics, genomics, proteomics, and new modalities have changed what drugs act on, especially for diseases lacking therapies.
- What they did: This Review synthesizes and quantifies trends in the number and types of drug targets and therapeutic modalities over the last 25 years, including counts of biomolecules and drugs.
- The result: The analysis shows how target druggability is evolving with emerging modalities, informing expectations for how the target landscape may continue to change.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.